Adjuvant Therapies and Markers of Post-Surgical Minimal Residual Disease II: Adjuvant Therapies of the Various Primary Tumors

ISBN-13: 9783642813344 / Angielski / Miękka / 2012 / 468 str.

Gianni Bonadonna; G. Mathe; S. E. Salmon

Opis

A prospective randomized clinical trial of treatment with vincristine, cyclophosphamide, methotrexate and 5-fluorouracil after conventional curative treatment for stage II breast cancer is described. The results at 2 years are recorded together with details of toxicity. Future plans are discussed briefly. Acknowledgement We wish to acknowledge the participation of all the collaborators in this study, the co-ordinator Dr. ERICA MANSBACHER and the support of Action Cancer in Belfast. References 1. Ahmann, D. L. , O'Connell, M. J. , Hahn, R. G. , Bisel, H. F. , Lee, R. A. , Edmonson, J. H. : An evaluation of early or delayed adjuvant chemotherapy in premenopause1 patients with advanced breast cancer undergoing oophorectomy. New Engl. J. Med. 297, 356-360 (1977) 2. Ahmann, D. L. , Scanlon, P. W. , Bisel, H. F. , Edmonson, J. H. , Frytak, S. , Payne, W. S. , O'Fallon, J. R. , Hahn, R. J. , Ingle, J. N. , O'Connell, M. J. , Rubin, J. : Repeated adjuvant chemotherapy with Phenyl-alanine mustard, or 5-Fluorouracil, Cyclophosphamide and Prednisone with or without radiation after mastectomy for breast cancer. Lancet 1978//, 893-896 3. Bonadonna, G. , Rossi, A. , Valagussa, P. , Banfi, A. , Veronesi, U. : The CMF program for operable breast cancer with positive axillary nodes. Cancer 39, 2904-2915 (1977) 4. Edelstyn, G. A. , Bates, T. S. , Brinkley, D. , Macrae, K. D. , Spittle, M. , Wheeler, T. : Comparison of 5-day, I-day and 2-day cyclical combination chemotherapy in advanced breast cancer.

Spis treści

B. Wilms’ Tumor and Sarcomas.- Wilms’ Tumor: Assessment and Treatment of Residual Disease.- Adjuvant Therapy in the Management of Osteosarcoma: Need for Critical Reassessment.- Adjuvant Therapy of Operable Primary Osteosarcoma-Cancer and Leukemia Group B Experience.- Adriamycin in the Adjuvant Treatment of Operable Osteosarcoma.- Randomized Trial of Adjuvant Chemotherapy in Osteogenic Osteosarcoma Comparison of Altering Sequential Administrations of High Doses of Adriamycin, Methotrexate, and Cyclophosphamide with a 6-Month Administration of High-Dose Adriamycin Followed by a Low-Dose Semicontinuous Chemotherapy. EORTC-Osteosarcoma Working Party Group.- Biochemistry of the Citrovorum Factor Rescue Effect in Normal Bone Marrow Cells After High-Dose Methotrexate Treatment: Implications for Therapy.- Adjuvant Interferon Treatment of Human Osteosarcoma.- Current Results With a Combined Treatment Approach to Localized Ewing’s Sarcoma.- EORTC/GTO Adjuvant Chemotherapy Program for Primary Ewing’s Sarcoma: Results at 5 Years.- Adjuvant Treatment of Soft Tissue Sarcoma in Children and Adults.- C. Breast Carcinoma.- Place and Role of Radiotherapy After Surgery for Breast Cancer.- Combined Modality Management of Operable Breast Cancer.- Treatment of Early Breast Cancer With Adriamycin-Cyclophosphamide With or Without Radiation Therapy: Initial Results of a Brief and Effective Adjuvant Program.- Results of a Randomized Trial of Prophylactic Chemotherapy in T3–T4 Breast Cancer Patients Previously Treated by Radiotherapy.- Four Drug Combination Cytotoxic Chemotherapy Following Surgery for Breast Cancer.- Pilot Study on Adjuvant Chemotherapy and Hormonal Therapy for Irradiated Inoperable Breast Cancer.- Ovarian Irradiation and Prednisone Following Surgery and Radiotherapy for Carcinoma of the Breast.- Adjuvant Therapy of Stage II, III Breast Cancer.- Randomized Trial With Poly A — Poly U as Adjuvant Therapy Complementing Surgery in Patients With Breast Cancer: In vitro Study of Cellular Immunity.- Levamisole: As Adjuvant to Cyclic Chemotherapy in Breast Cancer.- D. Ovary, Uterus and Testis Cancer.- Laparoscopy and Peritoneal Cytology as Markers in the Follow-Up of Ovarian Epithelial Tumors.- Radiotherapy in Ovarian Cancer for Post-Surgical Minimal Residual Disease.- Chemotherapeutic Sensitivity of Minimal Residual Disease Following Surgical Excision of Ovarian Carcinoma.- Chemoimmunotherapy for Advanced Ovarian Carcinoma With Adriamycin-Cyclophosphamide ± BCG: Early Report of a Southwest Oncology Group Study.- Active Specific Immunotherapy in Ovarian Cancer.- Clinical Studies on PSK: Combination Therapy of PSK With Radiation in Cancer of the Uterine Cervix.- Irradiation as Adjuvant Therapy in the Management of Testicular Tumors.- Adjuvant Chemotherapy in Embryonal Carcinoma of the Testis.- Adjuvant Chemotherapy of Testicular Carcinoma: Need for Evaluation of Curative Strategies.- Results of Cytostatic Therapy of Metastasizing Testicular Tumors.- E. Digestive Tract Tumors.- Treatment of Patients With Gastric Cancer by Surgery, Radiotherapy, and Chemotherapy: Preliminary Results of an EORTC Randomized Study.- Chemotherapy for Known Residual Disease After Resection of Gastric and Colorectal Cancer.- Adjuvant Treatment With Razoxane (ICRF 159) Following Resection of Cancer of the Stomach..- Adjuvant Chemotherapy in Large-Bowel Cancer: Demonstration of Effectiveness of Single Agent Chemotherapy in a Prospectively Controlled, Randomized Trial.- Ongoing Trials in the Surgical Adjuvant Management of Colorectal Cancer.- Clinical Studies on PSK: Combination Therapy of PSK With Surgery and Chemotherapy.- F. Bronchus Carcinoma.- Role of Radiotherapy as an Adjuvant Therapy in Operable Bronchus Carcinoma.- Influence of Postoperative Radiotherapy on Local Recurrence and Survival of Bronchial Epidermoid Carcinoma With Regard to Nodal Status: Preliminary Results of the EORTC Protocol 08741.- Preliminary Trends of the EORTC Study Comparing Postoperative Chemotherapy, Immunotherapy, Chemoimmunotherapy or Abstention in Squamous Cell Bronchial Carcinoma.- Adjuvant Chemotherapy of Post-Surgical Minimal Residual Bronchial Carcinomas.- Attempt at Immunotherapy With Living BCG in Patients With Bronchus Carcinoma.- Adjuvant Therapy With Levamisole in Resectable Lung Cancer.- Specific Active Imunochemotherapy in Lung Cancer: A Survival Study.- Patterns of Recurrence After Regional BCG Immunotherapy of Bronchial Cancer.- Intrapleural BCG in Operable Lung Cancer.- G. Head and Neck Tumors.- Adjuvant Chemoimmunotherapy of Head and Neck Cancer.- Adjuvant Treatment of Tongue and Floor of the Mouth Cancers.- First Results of a Randomized Trial on Immunotherapy of Head and Neck Tumors.- Adjuvant Trial of Levamisole in Patients With Squamous Cancer of the Head and Neck: A Preliminary Report.- H. Urological Tumors.- Adjuvant Chemotherapy Following Radical Radiotherapy in T3 Bladder Carcinoma.- Adjuvant Therapy of T1 Bladder Carcinoma: Preliminary Results of an EORTC Randomized Study.- I. Melanoma.- Adjuvant Chemotherapy or Chemoimmunotherapy in the Management of Primary Malignant Melanoma of Level III, IV, or V.- Immunotherapy for Recurrent Malignant Melanoma: Efficacy of BCG in Prolonging the Postoperative Disease-Free Interval and Survival.- Results of a Nonrandomized Trial in Malignant Melanoma Patients (Clark’s Stages III–V) Treated by Post-Surgical Chemoimmunotherapy.- Value of Adjuvant Therapy With Bacille Calmette Guerin (BCG) or Dimethyl Triazeno Imidazole Carboximide (DTIC) in the Control of Minimal Residual Disease in Stage II Melanoma.- Controlled Study for Prolonged Chemotherapy, Immunotherapy, and Chemotherapy Plus Immunotherapy as an Adjuvant to Surgery in Malignant Melanoma (Trial 6) Preliminary Report.- Adjuvant Therapy in Malignant Melanoma: A Trial of Immunotherapy, Chemotherapy, and Combined Treatment.- Malignant Melanoma (Stage I): A Clinical Trial of Adjuvant BCG Immunotherapy.- J. Neurological Tumors.- Adjuvant Chemotherapy With Nitrosourea Compounds Following Surgery Plus Radiotherapy in Glioblastoma Multiforme.- Treatment of Adult Malignant Gliomas.- Adjuvant Chemotherapy in Malignant Brain Gliomas.- Adjuvant Therapy for Residual Disease in Children With Medulloblastoma.- Radiochemotherapy of Postoperative Minimal Residual Disease in Neuroblastoma.- K. Tumors Not Yet Submitted to Adjuvant Chemotherapy and Immunotherapy Trials.- Adjuvant Systemic Therapy of Cancer: Rationale for Future Trials.- Some New Chemotherapeutic Agents and Combinations Possibly Available for New Adjuvant Therapies of Minimal Disease.- Third Generation of Systemic Adjuvants of Immunity: Experimental Basis for Adjuvant Combinations.- Interrelationship Between Chemotherapy and Immunotherapy in the Treatment of Disseminated Disease.- Concluding Remarks.